[在慢性病中使用塞马格卢提德:非常热情. 但它是如何工作的?]
Fiorella Iorio1, Chiara Summaria1, Rosita Greco1
1Division of Nephrology, Dialysis and Transplantation, Annunziata Hospital, Cosenza, Italy.
概括
类似葡萄糖-1 (GLP-1) 受体激动剂,如塞马格卢提德,在慢性病 (CKD) 患者中显示出保护脏和心脏的潜力. 这些药物可以改善结果,特别是与其他CKD疗法相结合时.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 慢性病 (CKD) 影响全球10%的人口,是全球第五大死亡原因.
- 慢性病显著增加了心血管事件和末期病的风险.
- 现有的治疗方法,如SGLT2抑制剂,矿物质皮质糖类受体对抗剂和内甲素受体对抗剂,在控制CKD进展和心风险方面存在局限性.
研究的目的:
- 探索GLP-1受体激动剂在CKD和2型糖尿病患者中的脏保护和心脏保护机制.
- 专门研究塞马格卢提德对该患者群体心脏脏结局的直接和间接影响.
主要方法:
- 关于GLP-1受体激动剂的当前文献的综述,重点是塞马格卢提德.
- 在CKD和2型糖尿病的背景下,分析了拟议的直接和间接作用机制.
- 讨论联合治疗对控制心风险的潜在益处.
主要成果:
- GLP-1受体激动剂在CKD中表现出有希望的脏保护和心脏保护作用.
- 塞马格卢提德通过各种直接和间接途径表现出改善预后的潜力.
- 涉及GLP-1受体激动剂的组合疗法可能为CKD患者提供增强的益处.
结论:
- 塞马格卢提德是减轻慢性病和2型糖尿病患者心脏脏风险的有前途的治疗选择.
- 为了优化其临床应用,需要对塞马格卢提德的特定机制进行进一步的研究.
- GLP-1受体激动剂,特别是塞马格卢提德,具有显著的潜力,可以改善CKD的管理和结果.
更多相关视频
07:01Delivery of Exogenous Artificially Synthesized miRNA Mimic to the Kidney Using Polyethylenimine Nanoparticles in Several Kidney Disease Mouse Models
Published on: May 10, 2022
1.6K
10:25Identification of the Source of Secreted Proteins in the Kidney by Brefeldin A Injection
Published on: November 10, 2021
1.8K
相关概念视频
01:24Glucagon-like Receptor Agonists
313
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
313
01:23Dipeptidyl Peptidase 4 Inhibitors
180
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
180
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
188
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
188
01:06Oral Hypoglycemic Agents: Glinides
152
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
152
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130